Petr Lesný, MD, PhD
Medicinal research and development, biomaterials and biotechnology, commercialization of innovative medical devices and quality management
Petr Lesný started to work as a researcher in the field of neurosciences during his studies at Charles University, continuing at the Institute of Experimental Medicine of the Academy of Sciences of the Czech Republic.
Over the long term, he has been involved in research of modern therapies based on innovative biomaterials and living cells (h-index 16). In order to apply the research results in practice, he has developed and implemented systems of good manufacturing practice in several biotechnology companies, among others within Bioinova, where he served as CEO in 2012-2013. In 2013 to 2014 he worked as the Coordinator for Advanced Therapies at the State Institute for Drug Control. He has now joined the Institute of Haematology and Blood Transfusion, where he leads a research program in the field of Immunotherapy of Haemato-Oncological Diseases and provides technological transfer knowhow, production and clinical trials for advanced and gene therapy products. Since 2014, he has been developing protocols for the manufacture of human stem cells, virus specific lymphocytes, natural killer cells and genetically modified lymphocytes.
He actively cooperates with regulatory bodies and innovative companies in the Czech Republic and within the EU with the aim to create the conditions for the development and commercialization of innovative medical devices and medicines for modern and gene therapies. He is also as an evaluator of EU projects.
Petr Lesný graduated in General Medicine and completed a Ph.D. in Neurosciences at Charles University in Prague, Czech Republic.